Renalytix to unveil interim results and host investor events

Published 12/03/2025, 13:02
Renalytix to unveil interim results and host investor events

LONDON and NEW YORK - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a company specializing in the commercialization of kidneyintelX.dkd, an FDA-approved prognostic test for early-stage chronic kidney disease risk assessment, is set to announce its unaudited interim results for the six months ending December 31, 2024. The results will be released on Tuesday, March 18, 2025.

In conjunction with the release of its financial results, Renalytix will hold two investor presentations to discuss the interim findings. Julian Baines, Executive Chairman of Renalytix, will conduct a live interactive presentation via the Engage Investor platform at 2:00 pm GMT on the same day as the results announcement. The presentation is open to all shareholders and potential investors, who are encouraged to pre-submit questions or pose them during the live event. Interested parties can register for the online event at no cost and access the recording afterward through their personalized investor hub on Engage Investor.

Additionally, an in-person presentation will take place at 5:30 pm GMT on Tuesday, March 25, 2025. This event, also led by Julian Baines, will be held at 75 King William Street, London, and is open to existing and potential shareholders. Attendees are welcome from 5:15 pm, with the presentation commencing at 5:30 pm, followed by refreshments.

These presentations aim to provide shareholders and interested investors with insights into the company’s performance over the past six months and its strategic direction moving forward.

Renalytix’s engagement with its investor base through these events reflects the company’s commitment to transparency and shareholder communication. The presentations are part of Renalytix’s efforts to keep the investment community informed about its progress and developments.

This article is based on a press release statement from Renalytix plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.